Adimmune

History

2017 - Present

Jan:Export of finished Enoxaparin sodium to Europe

  1. 2017 - Present
    • Jan:Export of finished Enoxaparin sodium to Europe

      Jul:Export of influenza vaccines to China and to Protein Sciences in the US

      Jul:Received marketing authorization for tetravalent influenza vaccine in Taiwan

      Aug:Complete enrollment for tetravalent influenza vaccine Phase III clinical trial in Europe

2016

Jan:Exported influenza vaccine antigen to Kitasato Daiichi Sankyo Co., Ltd. in Japan

  1. 2016
    • Jan:Exported influenza vaccine antigen to Kitasato Daiichi Sankyo Co., Ltd. in Japan
    • May:Short-listed for various provinces and cities of China, begin commercial export of trivalant influenza vaccine to China
    • Oct:Fill and finish line received US FDA GMP certification
    • Oct:Initiated tetravalent influenza vaccine clinical trial in Europe
2010 - 2015

Sep:Signed agreement with Kitasato Daiichi Sankyo Vaccine of Japan

  1. 2015
    • Sep:Signed agreement with Kitasato Daiichi Sankyo Vaccine of Japan
    • Nov:Rececived marketing authorization for trivalent influenza vaccine in China
  1. 2014
    • Jun:Aseptic fill and finish services contract with Protein Sciences Corporation in the US
  1. 2013
    • Apr:Aseptic fill and finish services contract with Shenzhen Techdow for European markets
    • Oct:Flu vaccine receives EMA certification from 15 European Nations
  1. 2012
    • May:Aseptic fill and finish line completed
    • Jun:Received marketing authorizations in EU countries for influenza vaccine, began supply of influenza vaccine antigen commercial supplies to Crucell
  1. 2011
    • Mar:Passed EU EMA GMP inspection and certification
2000 - 2010

Feb:Begin trial production of H5N1 vaccine and enterovirus 71 vaccine

  1. 2010
    • Feb:Begin trial production of H5N1 vaccine and enterovirus 71 vaccine
    • Sep:Begin supplying domestically produced influenza vaccine in Taiwan
  1. 2009
    • Jun:Influenza vaccine manufacturing facility completed
    • Nov:Received marketing authorization for H1N1 vaccine, manufactured and supplied 10 million doses of H1N1 vaccine for governmental pandemic prevention program
  1. 2008
    • Mar:Financial crisis, construction suspended for the third time
    • Jul:Dr. Chan Chi-Shean elected Chairman
    • Oct:Construction resumed for fourth time, multiple breakthrough on software, hardware, and scheduling
  1. 2007
    • Mar:Signed agreements with Crucell
    • Aug:Prof. Lee Ming-Liang elected Chairman
    • Nov:Contracts for aseptic room construction and equipments
  1. 2006
    • Mar:Construction suspended for the second time
    • Sep:Crucell visited Adimmune in Taiwan, begin negotiation for cooperation
  1. 2005
    • Jan:Signed technology transfer agreement for influenza vaccine with Kitasato, Japan
    • Jan:Contracted Sanki Chiyoda for basic and detail designs
  1. 2003
    • Aug:Construction suspended for the first time
  1. 2002
    • Nov:Completed steel frame construction for the vaccine plant
  1. 2001
    • May:Investment from Development Fund
    • Jun:Initiated project for plant construction
No Data
No Data